Premium
Topical valrubicin application reduces skin inflammation in murine models
Author(s) -
Hauge E.,
Christiansen H.,
Rosada C.,
de Darkó E.,
Dam T.N.,
Stenderup K.
Publication year - 2012
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.2012.10964.x
Subject(s) - inflammation , psoriasis , medicine , skin cancer , immunology , infiltration (hvac) , dermatology , cancer , physics , thermodynamics
Summary Background Valrubicin is a cytostatic anthracycline analogue, lacking toxicity by skin and tissue contact, and represents a new drug with potential for topical treatment of psoriasis and nonmelanoma skin cancer (NMSC); the beneficial effects have been partly explained by its antiproliferative and proapoptotic characteristics. Objectives To assess the effect of valrubicin on skin inflammation as inflammation also plays a key role in psoriasis and NMSC. Methods The effect of topical valrubicin treatment on skin inflammation in vivo was addressed in skin inflammation mouse models, where 12‐ O ‐tetradecanoylphorbol 13‐acetate was used to induce irritant contact dermatitis. An acute and a chronic model were included, to investigate the effect of valrubicin in short‐term inflammation and in more persistent inflammation. Inflammation‐associated ear oedema was evaluated by measuring ear thickness, infiltration of neutrophil cells, and expression of inflammatory cytokines, interleukin (IL)‐1β and IL‐6. Results Topical valrubicin treatment effectively reduced the inflammatory response in the acute and the chronic models. Conclusions The present data document an anti‐inflammatory effect of valrubicin, and may suggest an interesting new role for valrubicin in other debilitating skin diseases in which inflammation is a significant factor.